Clinical Trial Update: Phase II Iressa Versus Vinorelbine (INVITE) [Phase 2]

View source ↗

Summary

Phase II randomized trial INVITE comparing Iressa (gefitinib) to vinorelbine in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• Navelbine (vinorelbine)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small-Cell Lung Carcinoma | Phase 2 | Status: COMPLETED